<http://schema.org/articleBody>
"<p>\n\tBristol-Myers Squibb announced this week that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for Baraclude,to treat chronic hepatitis B in adults with liver disease.<br />\n\t<br />\n\tBaraclude uses the nucleotide analogue entecavir, which was first approved by the FDA in 2005 for treating chronic hepatitis B in adults with liver disease, InternalMedicineNews.com reports.<br />\n\t<br />\n\tBMS officials told InternalMedicineNews.com that the approval was based on virologic, biochemical, serologic and safety data from a controlled, ongoing, open-label Phase IIIb study.<br />\n\t<br />\n\tDr. Naoky Tsai, a professor of medicine at the John A. Burns School of Medicine at the University of Hawaii, Honolulu, told InternalMedicineNews.com the study compared Baraclude to adefovir.<br />\n\t<br />\n\tBaraclude was administered to random patients at a dosage of one milligram daily, while adefovir was given at a dosage of 10 milligram once daily. Tsai said data showed that Baraclude was effective in the patient population and showed a greater viral suppression compared to adefovir following a 48 week treatment initiation.<br />\n\t<br />\n\t&ldquo;This additional indication for Baraclude is important news as it is now proven to be an effective treatment option for physicians to help in managing chronic hepatitis B patients with decompensated liver disease,&rdquo; Tsai told InternalMedicineNews.com.<br />\n\t<br />\n\tDecompensated liver disease is the failure of the liver to maintain adequate function, often due to severe scarring.</p>\n"^^<http://www.w3.org/2001/XMLSchema#string>
<http://vaccinenewsdaily.com/stories/510531407-fda-approves-new-drug-to-treat-hepatitis-b>